Cost-Effectiveness Analyses of Vaccination Programmes

Cost effectiveness of rotavirus vaccines and other interventions for diarrhoeal diseases: meeting report 2006. Wkly Epidemiol Rec 2006; 81 (37): 350-3 World Health Organization. Vaccine introduction guidelines: adding a vaccine to a national immunization programme. Decision and implementation: report no. WHO/IVB/05.18. Geneva: WHO, 2005 Drummond MF, Sculpher MJ, Torrance GW, et al., editors. Methods for the economic evaluation of health care programmers. New York: Oxford University Press, 2005 Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996 Culyer AJ. The normative economics of health care finance and provision. Oxf Rev Ebon Pol 1989; 5: 34–58 Sloan FA, editor. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge (UK): Cambridge University Press, 1995 Johannesson M. Theory and methods of economic evaluation of health care. Dordrecht: Kluwer Academic Publishers, 1996 Drummond MF, McGuire A. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001 Donaldson C, Mugford M, Vale L, editors. Evidence-based health economics. London: BMJ Books, 2002 Muennig P. Designing and conducting cost-effectiveness analyses in medicine and health care. San Francisco (CA): Jossey-Bass, 2002 Haddix AC, Teutsch SM, Corso PS, editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. New York: Oxford University Press, 2003 Evans DB, Edejer TT, Adam T, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ 2005 Nov 12; 331: 1137–40 Brenzel L. Selecting an essential package of health services using cost-effectiveness analysis: a manual for professionals in developing countries. Data for Decision Making Project and PHN Department, The World Bank, 1993 [online]. Available from URL: http://www.hsph.harvard.edu/ihsg/publications/pdf/No-5.PDF [Accessed 2008 Feb 12] Jamison DT, Breman JG, Measham, et al., editors. Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press, 2006 Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003 National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 Apr [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/rAP_Methods.pdf [Accessed 2008 Jan 30] Menon D, Schubert F, Torrance GW. Canada’s new guidelines for the economic evaluation of pharmaceuticals. Med Care 1996; 34: DS77–85 Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997 Commonwealth of Australia. Guidelines for pharmaceutical industry and preparation of submissions to the Pharmaceuticals Benefits Advisory Committee: including economic analyses. Canberra: Department of Health and Community Services, 1995 Adam T, Evans DB, Murray CJL. Econometric estimation of country-specific hospital costs. Cost Eff Resourc Alloc 2003; 1 (1): 3 Adam T, Koopmanschap MA, Evans DB. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care 2003; 19 (2): 407–20 Hutton G, Baltussen R. Cost valuation in resource-poor settings. Health Policy Plan 2005; 20: 252–9 Johns B, Adam T, Evans DB. Enhancing the comparability of costing methods: cross-country variability in the prices of non-traded inputs to health programmes. Cost Eff Resourc Alloc 2006; 4: 8 Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resourc Alloc 2003; 1 (1): 1 Johns B, Torres TT, WHO-CHOICE. Costs of scaling up health interventions: a systematic review. Health Policy Plan 2005; 20: 1–13 Mulligan J, Fox-Rushby JA, Adam T, et al. Unit costs of health care inputs in low and middle income regions: DCPP working paper no. 9. Bethesda (MD): Disease Control Priorities Project, Fogarty International Center, National Institutes of Health, 2005 Batt K, Fox-Rushby JA, Castillo-Riquelme M. The costs, effects and cost-effectiveness of strategies to increase coverage of routine immunizations in low-and middle-income countries: systematic review of the grey literature. Bull World Health Organ 2004; 82: 689–96 Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system. Geneva: WHO/Department of Vaccines and Biologicals, 2002 Wolfson LJ, Gasse F, Lee-Martin S, et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006–2015. Bull World Health Organ 2008; 86: 27–39 Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16 (1): 33–64 Elbasha EH, Messonnier ML. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Econ 2004; 13 (1): 21–35 Poulos C, Whittington D. Time preferences for life-saving programs: evidence from six less developed countries. Environ Sci Technol 2000; 34 (8): 1445–55 Jamison DT, Jamison JS. Discounting: DCPP working paper no. 4. Bethesda (MD): Disease Control Priorities Project, Fogarty International Center, National Institutes of Health, 2003 Musgrove P, Fox-Rushby J. Cost-effectiveness for priority setting: disease control priorities in developing countries. 2nd ed. New York: Oxford University Press, 2006: 271–86 Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003; 41 (1): 32–44 Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9 (8): 681–98 Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17: 461–77 Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976–2001. Value Health 2005; 8 (1): 3–9 Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a subtable of “panel-worthy” studies. Med Decis Making 2000; 20: 451–67 Bell CM, Chapman RH, Stone PW, et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001; 21: 288–94 Stone PW, Schackman B, Neukermans CP, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 2005; 5: 383–91 Bloom DE, Canning D, Weston M. The value of vaccination. World Econ 2005; 6 (3): 15–39 Brenzel L, Wolfson LJ, Fox-Rushby J, et al. Vaccine-preventable diseases. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd ed. Oxford (UK): Oxford University Press and the World Bank, 2006: 389–411 Beutels P, Van Doorslaer E, Van Damme P, et al. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003; 2: 649–60 Kaddar M, Lydon P, Levine R. Financial challenges of immunization: a look at GAVI. Bull World Health Organ 2004; 82: 697–702 Beutels P. Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. Antwerpen: UA, UIA, Faculteit Biomedische Wetenschappen, 2002 Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006 Sep–Oct; 26 (5): 434–46 Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd immunity. Med Decis Making 2003; 23: 76–82 Goldie SJ, Goldhaber-Fiebert, Garnett G. Public health policy for cervical cancer prevention: role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006: 24 Suppl. 3; S155–S163 Garnett G, Kim JJ, French K, et al. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006: 24 Suppl. 3: SI78–86 Bos JM, Beutels P, Annemans L, et al. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 2004; 22 (18): 1171–9 Beutels P. Economic evaluations applied to HB vaccination: general observations. Vaccine 1998; 16 Suppl.: S84–92 Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999; 5 (3): 336–45 Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV 16/18 vaccine. Int J Cancer 2003; 106: 896–904 Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997 May; 6 (3): 217–27 Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for healthcare and other policy decisions: uses, roles, and validity. Value Health 2001 Sep; 4 (5): 348–61 Allman ES, Rhodes JA. Mathematical models in biology: an introduction. Cambridge (UK): Cambridge University Press, 2004 Office of Health Economics. From efficacy to cost-effectiveness [OHE briefing, no 37]. London: OHE, 1998 May Briggs A, Sculpher M, Claxton K, editors. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006 Hunink MGM, Glasziou P, Siegel J, et al. Decision making in health and medicine: integrating evidence and values. Cambridge (UK): Cambridge University Press, 2001 Kuntz KM, Weinstein MC. Modeling in economic evaluation. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 141–71 Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991 Anderson RM, Garnett GP. Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis 2000; 27: 636–43 Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140: 81–104 Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18: 3263–82 Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Inf 2002; 78: 7–12 Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005 Feb 1; 191 Suppl. 1: S97–106 Davies R, Davies HTO. Modelling patient flows and resource provision in health systems. Omega Int J Mngt Sci 1994; 22: 123–31 Karnon J. Alternative decision modeling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ 2003; 12: 837–48 Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004; 9: 110–8 Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38 Law AM, Kelton WD. Simulation modeling and analysis. 3rd ed. Boston (MA): McGraw-Hill, 2000 Chick SE, Adams AL, Koopman JS. Analysis and simulation of a stochastic, discrete-individual model of STD transmission with partnership concurrency. Math Biosci 2000; 166: 45–68 Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): iii–iv, ix-xi, 158 Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modeling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355–71 Weinstein MC, O’Brien B, Hornberger J, et al, ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in healthcare evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 6: 9–17 Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20: 1–7 Spier R, Jeffereson T, Demicheli V. An editorial policy statement: submission of economic evaluations of vaccines. Vaccine 2002; 20: 1693–5 Szucs TD. Health economic research on vaccinations and immunization practices: an introductory primer. Vaccine 2005; 23: 2095–103 Hinman AR, Irons B, Lewis M, et al. Economic analysis of rubella and rubella vaccines: a global review. Bull World Health Organ 2002; 80: 264–70 Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 2003; 37: 44–51 Postma MJ, Bos JM, Beutels P, et al. Pharmacoeconomic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 2004; 22: 1862–7 Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10: 751–74 Miller MA, Shahab CK. Review of the cost-effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. Pharmacoeconomics 2005; 23: 333–43 Welte R, Trotter C, Edmunds J, et al. The role of economic evaluation in vaccine decision making: focus on meningococcal C vaccination. Pharmacoeconomics 2005; 23 (9): 855–74 De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004; 22: 719–40 Thiry N, Beutels P, Van Damme P. Economic evaluations of pneumococcal vaccination strategies in adults: a summary of the results. Acta Clin Belg 2005; 60 (6): 338–44 Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002–2006). Vaccine 2007; 25 (8): 1355–67 Brinsmead R, Hill S, Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 2004; 23: 32–7 Burls A, Jordan R, Barton P, et al. Vaccinating healthcare workers against influenza to protect the vulnerable: is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006; 24: 4212–21 Caro JJ, Getsios D, Payne K, et al. Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis J 2005; 24: S48–54 Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7: 289–96 Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88–100 Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38 Walker DG, Rheingans R. Cost-effectiveness of rotavirus vaccines. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5 (5): 593–601 Cooper K, Brailsfor SC, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc 2007; 58: 168–76 Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15: 1295–310 Sulistio A, Yeo CS, Buyya R. A taxonomy of computer-based simulations and its mapping to parallel and distributed systems simulation tools. Softw Pract Exper 2004; 34: 653–73 Lipsitch M, Cohen T, Cooper B, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 2003; 300 (5627): 1966–70 Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000 Jul–Sep; 20 (3): 314–22 Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (4): 1043–53 Bonabeau E. Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci USA 2002; 99: 7280–7 Darley V, von Tessin P, Sanders D. An agent-based model of a corrugated box factory: the tradeoff between finished-goods stock and on-time-in-full delivery. In: Coelho H, Espinasse B, editors. Proceedings of the 5th Workshop on Agent-Based Simulation; 2004 May 3–5; Lisbon. Society for Modelling and Simulation Europe BVBA, 2004 Muller G, Grebaut P, Gouteux JP. An agent-based model of sleeping sickness: simulation trials of a forest focus in southern Cameroon. C R Biol 2004 Jan; 327 (1): 1–11 Scott A. A computing strategy for SAGE: 1. Model options and constraints. SAGE technical note no 2. London: Simulating Social Policy in an Ageing Society (SAGE), August 2001 [online]. Available from URL: http://www.lse.ac.uk/collections/sage/pdf/sage_tn2.pdf [Accessed 2008 Jan 30] Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 2007 Jan 10; 25 (2): 203–8 Feuer EJ, Etzioni RD, Cronin KA, et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004; 13: 421–42 Feuer EJ. Modeling the impact of adjuvant therapy and screening mammography on US breast cancer mortality between 1975 and 2000: introduction to the problem. J Natl Cancer Inst Monogr 2006; 36: 2–6 National Cancer Institute, Cancer Intervention and Surveillance Monitoring Network (CISNET) [online]. Available from URL: http://www.cisnet.cancer.gov [Accessed 2007 Oct 22] Dewilde S, Anderson R. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer. Med Decis Making 2004; 24: 486–92 Aris R. Mathematical modelling techniques. New York: Dover, 1994 Wooldridge JM. Introductory econometrics: a modern approach. 2nd ed. Cincinnati (OH): South-Western, 2003 Coudeville L, Brunot A, Giaquinto C, et al. Varicella vaccination in Italy. Pharmacoeconomics 2004; 22 (13): 839–55 World Health Organization. WHO-CHOICE: World Health Organization statistical information system. CHOICE (CHOosing Interventions that are Cost Effective) [online]. Available from URL: http://www.who.int/choice/en/ [Accessed 2007 Oct 22] Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996 Fryback DG, Stout NK, Rosenberg MA, et al. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr 2006; 36: 37–47 Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3 (2): 95–104 Walker D, Fox-Rushby J. Allowing for uncertainty in economic evaluations: qualitative sensitivity analysis. Health Policy Plan 2001; 16 (4): 435–43 Baltussen RM, Hutubessy RC, Evans DB, et al. Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care 2002; 18 (1): 112–9 Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10 (8): 779–87 Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13 (5): 405–15 Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005; 187: 106–8 Fenwick E, Briggs A. Cost-effectiveness acceptability curves in the dock: case not proven? Med Decis Making 2007; 27 (2): 93–5 Groot Koerkamp B, Hunink MGM, Stijnen T, et al. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making 2007; 27 (2): 101–11 Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377–401 Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV 16,18 vaccination in Brazil. Vaccine 2007; 25 (33): 6257–70 Salomon JA, Weinstein MC, Hammitt JK, et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156: 761–73 Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166 (2): 137–50 Hutubessy RC, Baltussen RM, Evans DB, et al. Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ 2001; 10 (5): 473–7 Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8 (49): iii–iv, 192 Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA 2002; 287: 2809–12 Sassie F, Archard L, McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? Medical Care 2002; 40: 387–94 Cooper K, Brailsford SC, Davies R, et al. A review of health care models for coronary heart disease interventions. Health Care Mngt Sci 2006; 9 (4): 311–24 Kim JJ, Andres-Beck B, Goldie S J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007 Nov 5; 97 (9): 1322–8 Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness analysis of HPV-DNA testing and prophylactic HPV vaccination for the prevention of cervical cancer in the U.S. J Natl Cancer Inst. In press Goldhaber-Fiebert JD, Stout NK, Ortendahl JO, et al. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5: 11 Hammerschmidt T, Goertz A, Wagenpfeil S, et al. Validation of health economic models: the example of EVITA. Value Health 2003; (5): 551–9 Shepard DS, Walsh JA, Kleinau E, et al. Setting priorities for the Children’s Vaccine Initiative: a cost-effectiveness approach. Vaccine 1995; 13 (8): 707–14 Fine PEM. The contribution of modeling to vaccination policy. In: Cutts FT, Smith PG, editors. Vaccination and world health. West Sussex: John Wiley & Sons, 1994: 177–94